Rheumatoid Arthritis Update
|
|
- Philomena Pitts
- 5 years ago
- Views:
Transcription
1 Rheumatoid Arthritis Update Beth Valashinas, DO, FACOI, FACR Disclosures Speaker for AbbVie Pharmaceuticals Learning Objectives Upon completion of this session, participants should be able to discuss: The paradigm shift in treatment of RA Recent changes in classification criteria for RA Treat-to-target (T2T) Recommendations 2015 ACR recommendations for treatment of RA DMARDs, Biologics, and other novel RA therapies 1
2 Clinical Case #1 47 y.o. female with recently diagnosed RA is currently maintained on oral methotrexate at 20mg once weekly in addition to prednisone 5mg daily. Recent labs included an ESR of 12mm/hr and elevated CRP at 10mg/L. She has 2 tender joints and 2 swollen joints on exam, global health evaluation of 10/100, and DAS 28 score of 3.06 indicating moderate disease activity. Recent hand XR reveal marginal erosions on bilateral 2 nd MCPs. Clinical Case #1 Question Which of the following would be the best treatment option at this time? A.) Increase methotrexate to 25mg once weekly B.) Increase prednisone to 10mg daily C.) Add sulfasalazine or hydroxychloroquine D.) Add a TNF inhibitor E.) Change to parenteral methotrexate Clinical Case #2 67 y.o. female with history of long-standing RA and HTN presents for a routine follow up and inquires about immunizations. Her RA has been well controlled on Enbrel, parenteral methotrexate 25mg once weekly, and prednisone 5mg daily. 2
3 Clinical Case #2 Question All of the following vaccines are appropriate to give as indicated EXCEPT: A.) Pneumococcal B.) Hepatitis B C.) Herpes Zoster D.) Influenza (IM) Clinical Case #3 64 y.o. female presents with an inflamed left PIP joint as well as tenderness of all PIPs, DIPs, and bilateral knees. She relates long-standing joint discomfort and laboratory evaluation reveals a negative RF and anti-ccp Ab. Both ESR and CRP are normal. Clinical Case #3 Question Does she meet criteria for diagnosis of RA based on the 2010 ACR/EULAR Criteria? A.) Yes B.) No 3
4 Clinical Case #4 53 y.o. male with history of RA and NYHA Class III CHF presents for routine follow up visit. He has been maintained on oral methotrexate 20mg once weekly for his RA and relates recurrent flare activity. He has multiple tender and swollen joints on exam and DAS28 score is 4.7, consistent with moderate disease activity. Clinical Case #4 Question All of the following would be potential treatment options EXCEPT: A.) Change to parenteral methotrexate for better bioavailability B.) Add Abatacept (Orencia) C.) Add a TNF inhibitor D.) Add sulfasalazine and hydroxychloroquine for triple therapy Clinical Case #5 42 y.o. male who presents with a 4 week history of polyarticular joint pain. On exam, he has tenderness and synovitis involving bilateral 2 nd -4 th MCPs. Laboratory evaluation reveals negative RF and anti-ccp Ab. ESR is normal, but CRP is elevated. 4
5 Clinical Case #5 Question Does he meet criteria for RA according to the 2010 ACR/EULAR Criteria? A.) Yes B.) No Rheumatoid Arthritis Affects 1% of population worldwide Risk increases with age as affects ~6% of Caucasian population >65 years of age Higher prevalence in women 3.6% female vs. 1.7% male lifetime risk Morbidity/Mortality associated with RA >1/3 of patients with RA experience work disability due to their disease RA is associated with a 50% increased risk for MI and >2-fold increased risk for CHF RA shortens life expectancy by 3-5 years Includes extra-articular disease as well as treatment-related adverse effects 5
6 Evidence of early radiographic progression contributes to paradigm shift Studies in very early RA indicate early radiographic progression 63.6% of patients developed erosive disease within 3 years 74.3% in first year 97.2% by second year Strongly associated with positive ACPA, RF, and high long-term disease activity K.P. Machold, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of the disease. Rheumatology. 2007; 46: ACR/EULAR Classification Criteria for RA Established by an international task force Designed to be used in patients with clinical synovitis in at least one joint Classification criteria, not diagnostic criteria Serves as a guide 6
7 7
8 8
9 Treating RA to target: The T2T International Task Force 2014 Update Principles Treatment must be based on shared decision between patient and rheumatologist Primary goal is to maximize long-term healthrelated quality of life Abrogation of inflammation most important way to achieve goal T2T by measuring disease activity and adjusting therapy to optimize outcomes in RA 9
10 10 recommendations of T2T committee 1. Primary target in treatment of RA should be state of clinical remission 2. Clinical remission is defined by absence of signs and symptoms of significant inflammatory disease activity 3. While remission is goal, low disease activity may be acceptable alternative, especially in longstanding disease 10 recommendations of T2T committee 4. Until desired target met, drug therapy should be adjusted at least every 3 months 5. Measures of disease activity must be obtained frequently (monthly for moderate/high disease activity or every 3-6 months for low disease activity/clinical remission) 6. Use of validated composite measures of disease activity, including joint assessment, needed to guide treatment decisions 10 recommendations of T2T committee 7. Structural changes and functional impairment should be considered in treatment decisions 8. Desired treatment target should be maintained throughout course of disease 9. Choice of composite measure of disease activity and level of target value may be influenced by comorbidities, patient factors, and drug-related risks 10. Patient should be informed of target and strategy planned to reach target under supervision of rheumatologist 10
11 Composite Disease Activity Measurement Disease activity score (DAS 28) Simplified disease activity index (SDAI) Clinical disease activity index (CDAI) Tender joint count (0-28) Swollen joint count (0-28) ESR or CRP Patient s global assessment on VAS(0-100) Tender joint count (0-28) Swollen joint count (0-28) CRP Patient s global assessment on VAS(0-100) Physician s global assessment on VAS(0-100) Tender joint count (0-28) Swollen joint count (0-28) Patient s global assessment on VAS(0-100) Physician s global assessment on VAS(0-100) Remission score <2.6 Remission score </= 3.3 Remission score </= 2.8 Novel measure of disease activity Vectra DA Blood test which measures 12 biomarkers linked to RA inflammation and produces a composite score between indicating low, moderate, or high disease activity Clinical validation in both RF, ACPA positive and seronegative RA patients DMARDs (Disease modifying antirheumatic drugs) Methotrexate Approved in 1988 Remains cornerstone of RA therapy Often used in combination with other DMARDs, biologic therapies Leflunomide (Arava) Hydroxychloroquine (Plaquenil) Sulfasalazine Triple therapy (methotrexate, hydroxychloroquine, and sulfasalazine) 11
12 Potential side effects/adverse effects of DMARDs Methotrexate Nausea, fatigue, alopecia, hepatotoxicity, lowered blood counts, pneumonitis, immunosuppression Hydroxychloroquine Rash, increased sun sensitivity, skin discoloration, rare eye toxicity Leflunomide (Arava) Nausea, diarrhea, alopecia, hepatotoxicity, lowered blood counts, immunosuppression Sulfasalazine Nausea, vomiting, lowered blood counts, rash Triple therapy vs. Etanercept+MTX Biologic therapy for RA Tumor necrosis factor (TNF) inhibitors Etanercept (Enbrel) Approved in 1998 Soluble TNF receptor fusion protein Infliximab (Remicade) Chimeric monoclonal antibody Adalimumab (Humira) Fully monoclonal antibody 12
13 Biologic therapy for RA Tumor necrosis factor (TNF) inhibitors Golimumab (Simponi) Human monoclonal antibody Certolizumab pegol (Cimzia) Pegylated Fab fragment of a humanized monoclonal antibody Mechanism of action in anti-tnf therapy Potential side effects/adverse effects of TNF inhibitors Injection site reactions, upper respiratory tract infections, immunosuppression, reactivation of TB/latent fungal infections, malignancy, infusion reactions (Remicade) Avoid in CHF (especially NYHA Class III-IV), previously treated or untreated skin cancer (nonmelanoma or melanoma), and previously treated lymphoproliferative disorders 13
14 Biologic therapy for RA Abatacept (Orencia) Selective T cell costimulation modulator which inhibits T cell (T lymphocyte) activation by binding to CD80 and CD86, thereby blocking interaction with CD28 Activated T lymphocytes are implicated in the pathogenesis of RA and are found in the synovium of patients with RA. Orencia decreases T cell proliferation and inhibits the production of the cytokines TNF alpha (TNFα), interferon-γ, and interleukin-2. Biologic therapy for RA Abatacept (Orencia) Potential adverse effects Headache, immunosuppression, serious infections, infusion reactions, malignancy, COPD exacerbations Biologic therapy for RA Tocilizumab (Actemra) Humanized monoclonal antibody that binds to interleukin-6 (IL-6) receptors and inhibits IL-6 mediated signaling IL-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T- and B-cells, lymphocytes, monocytes and fibroblasts. IL-6 is also produced by synovial and endothelial cells leading to local production of IL-6 in joints affected by RA 14
15 Biologic therapy for RA Tocilizumab (Actemra) Potential adverse effects Serious infections, immunosuppression, lowered blood counts, elevated LFTs, gastrointestinal perforation, reactivation of TB/fungal infections, hyperlipidemia Biologic therapy for RA Rituximab (Rituxan) Chimeric monoclonal antibody against CD20 antigen present on surface protein of B cells which mediates B-cell lysis. B cells believed to play a role in pathogenesis of RA and associated synovitis, thus Rituxan may interfere with production of autoantibodies, antigen presentation, T-cell activation, and/or cytokine production Biologic therapy for RA Rituximab (Rituxan) Potential adverse effects Serious infections, infusion reactions, reactivation of JC virus causing incurable progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation, cardiovascular events 15
16 Janus kinase (JAK) inhibitor Tofacitinib (Xeljanz) Modulates the signaling pathway of JAKs (intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on cell membranes influencing immune cell function) by preventing phosphorylation and activation of Signal Transducers and Activators of Transcription (STATs), which modulate intracellular activity including gene expression. Janus kinase (JAK) inhibitor Tofacitinib (Xeljanz) Potential adverse effects Serious infections, reactivation of TB/fungal infections, malignancy, lowered blood counts, elevated LFTs, hyperlipidemia, gastrointestinal perforation 2015 American College of Rheumatology Guidelines for treatment of early RA 16
17 2015 ACR recommendations for treatment of established RA 2015 ACR recommendations for treatment of established RA Clinical Case #1 revisited 47 y.o. female with recently diagnosed RA is currently maintained on oral methotrexate at 20mg once weekly in addition to prednisone 5mg daily. Recent labs included an ESR of 12mm/hr and elevated CRP at 10mg/L. She has 2 tender joints and 2 swollen joints on exam, global health evaluation of 10/100, and DAS 28 score of 3.06 indicating moderate disease activity. Recent hand XR reveal marginal erosions on bilateral 2 nd MCPs. 17
18 Clinical Case #1 Question Which of the following would be the best treatment option at this time? A.) Increase methotrexate to 25mg once weekly B.) Increase prednisone to 10mg daily C.) Add sulfasalazine or hydroxychloroquine D.) Add a TNF inhibitor E.) Change to parenteral methotrexate Clinical Case #1 Question Which of the following would be the best treatment option at this time? A.) Increase methotrexate to 25mg once weekly B.) Increase prednisone to 10mg daily C.) Add sulfasalazine or hydroxychloroquine D.) Add a TNF inhibitor E.) Change to parenteral methotrexate Clinical Case #2 revisited 67 y.o. female with history of long-standing RA and HTN presents for a routine follow up and inquires about immunizations. Her RA has been well controlled on Enbrel, parenteral methotrexate 25mg once weekly, and prednisone 5mg daily. 18
19 Clinical Case #2 Question All of the following vaccines are appropriate to give as indicated EXCEPT: A.) Pneumococcal B.) Hepatitis B C.) Herpes Zoster D.) Influenza (IM) Clinical Case #2 Question All of the following vaccines are appropriate to give as indicated EXCEPT: A.) Pneumococcal B.) Hepatitis B C.) Herpes Zoster D.) Influenza (IM) Clinical Case #3 revisited 64 y.o. female presents with an inflamed left PIP joint as well as tenderness of all PIPs, DIPs, and bilateral knees. She relates long-standing joint discomfort and laboratory evaluation reveals a negative RF and anti-ccp Ab. Both ESR and CRP are normal. 19
20 Clinical Case #3 Question Does she meet criteria for diagnosis of RA based on the 2010 ACR/EULAR Criteria? A.) Yes B.) No Clinical Case #3 Question Does she meet criteria for diagnosis of RA based on the 2010 ACR/EULAR Criteria? A.) Yes B.) No (She appears to meet criteria for RA, but this is a case of erosive OA) Clinical Case #4 revisited 53 y.o. male with history of RA and NYHA Class III CHF presents for routine follow up visit. He has been maintained on oral methotrexate 20mg once weekly for his RA and relates recurrent flare activity. He has multiple tender and swollen joints on exam and DAS28 score is 4.7, consistent with moderate disease activity. 20
21 Clinical Case #4 Question All of the following would be potential treatment options EXCEPT: A.) Change to parenteral methotrexate for better bioavailability B.) Add Abatacept (Orencia) C.) Add a TNF inhibitor D.) Add sulfasalazine and hydroxychloroquine for triple therapy Clinical Case #4 Question All of the following would be potential treatment options EXCEPT: A.) Change to parenteral methotrexate for better bioavailability B.) Add Abatacept (Orencia) C.) Add a TNF inhibitor D.) Add sulfasalazine and hydroxychloroquine for triple therapy Clinical Case #5 42 y.o. male who presents with a 4 week history of polyarticular joint pain. On exam, he has tenderness and synovitis involving bilateral 2 nd -4 th MCPs. Laboratory evaluation reveals negative RF and anti-ccp Ab. ESR is normal, but CRP is elevated. 21
22 Clinical Case #5 Question Does he meet criteria for RA according to the 2010 ACR/EULAR Criteria? A.) Yes B.) No Clinical Case #5 Question Does he meet criteria for RA according to the 2010 ACR/EULAR Criteria? A.) Yes B.) No (This patient may have early seronegative RA and be classified prospectively) Summary RA is more common in women, affects ~1% of the worldwide population, and risk increases with age RA leads to disability in >1/3 of patients, decreases life expectancy, and increases cardiovascular risks Studies in very early RA indicate radiographic progression with evidence of erosive disease common within 2 years of diagnosis 22
23 Summary A paradigm shift in treatment of RA 2010 ACR/EULAR changes in classification criteria for RA 2014 update on treat-to-target (T2T) recommendations 2015 ACR recommendations for treatment of both early and established RA The primary target of treatment is clinical remission by employing early intensive therapies Summary The development of novel treatments including biologics often used in conjunction with DMARDs has transformed RA therapy and positively impacted the outcome of patients Balancing new developments with patient safety will remain important along with continued communication between the patient and rheumatologist regarding treatment strategy References 1. Helmick C.G., Felson D.T., Lawrence R.C., National Arthritis Data Workgroup Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I. Arthritis Rheum. 2008;58(1): [PubMed] 2. Crowson C.S., Matteson E.L., Myasoedova E. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63(3): [PMC free article] [PubMed] 3. Allaire S., Wolfe F., Niu J., Lavalley M.P. Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US. Arthritis Rheum. 2008;59(4): [PMC free article] [PubMed] 4. Sokka T., Kautiainen H., Pincus T., QUEST-RA Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther. 2010;12(2):R42. [PMC free article] [PubMed] 5. Turesson C., O'Fallon W.M., Crowson C.S., Gabriel S.E., Matteson E.L. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol. 2002;29(1): [PubMed] 6. Gabriel S.E., Crowson C.S., Kremers H.M. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum. 2003;48(1): [PubMed] 7. Lindhardsen J., Ahlehoff O., Gislason G.H. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis. 2011;70(6): [PubMed] 8. Semb A.G., Kvien T.K., Aastveit A.H. Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoproteinrelated Mortality RISk (AMORIS) Study [published online ahead of print June 15, 2010] Ann Rheum Dis. 2010;69(11): [PubMed] 9. Maradit-Kremers H., Crowson C.S., Nicola P.J. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a populationbased cohort study. Arthritis Rheum. 2005;52(2): [PubMed] 10. Nicola P.J., Crowson C.S., Maradit-Kremers H. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum. 2006;54(1): [PubMed] 11. Nicola P.J., Maradit-Kremers H., Roger V.L. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 2005;52(2): [PubMed] K.P. Machold, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of the disease. Rheumatology. 2007; 46: J.A. Singh, et al American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care and Research Smolen, J. S. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 69, (2010). 14. Smolen, J. S. et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann. Rheum. Dis. 23
24 Questions/Comments? 24
Treatment of Rheumatoid Arthritis: The Past, the Present and the Future
Treatment of Rheumatoid Arthritis: The Past, the Present and the Future Lai-Ling Winchow FCP(SA) Cert Rheum(SA) Chris Hani Baragwanath Academic Hospital University of the Witwatersrand Outline of presentation
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 6 Last Review Date: March 16, 2018 Xeljanz Description Xeljanz, Xeljanz
More informationRheumatoid Arthritis. Improving Outcomes in RA: Three Pillars. RA: Chronic Joint Destruction and Disability What We Try to Prevent
Rheumatoid Arthritis Modern Management of Common Problems in Rheumatology: Rheumatoid Arthritis Jonathan Graf, M.D. Associate Professor of Medicine, UCSF Division of Rheumatology, SFGH Director, UCSF Rheumatoid
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationRHEUMATOID ARTHRITIS DRUGS
Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More information(tofacitinib) are met.
Xeljanz (tofacitinib) Policy Number: 5.01. 560 Origination: 3/2014 Last Review: 3/2014 Next Review: 3/2015 Policy BCBSKC will provide coverage for Xeljanz (tofacitinib) when it is determined to be medically
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationFml Limits. Azathioprine (Imuran) 50mg, 75mg, 100mg - $26.85 Cyclosporine, 25mg, 100mg. $ Leflunomide (Arava) 10mg Tablet - $144.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Rheumatoid Arthritis (RA) P&T DATE: 2/15/2017 CLASS: Rheumatology/Anti-inflammatory Disorders REVIEW HISTORY 2/16, 5/15,
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and
More informationLecture: Rheumatology Update on DMARDs in Common Rheumatologic Diseases for the Family Physician. Sco Jay Harris, DO, FACFR
Lecture: Rheumatology Update on DMARDs in Common Rheumatologic Diseases for the Family Physician Sco Jay Harris, DO, FACFR UPDATE ON DMARDS, BIOLOGICALS, CYTOKINE INHIBITORS/B CELL DEPLETIONS/CO-STIMULATION
More informationPractical RA Treatment: James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014
Practical RA Treatment: 2014 James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014 Disclosures James R. O Dell PI of Multinational RA trial supported by VA and NIH (NIAMS) that receives
More informationCorporate Medical Policy
Corporate Medical Policy Rituximab for the Treatment of Rheumatoid Arthritis File Name: Origination: Last CAP Review: Next CAP Review: Last Review: rituximab_for_the_treatment_of_rheumatoid_arthritis 4/2008
More informationMedication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013
Medication Policy Manual Policy No: dru289 Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1,
More informationRheumatoid Arthritis Update. Whitney White, Pharm.D., BCPS Associate Professor of Pharmacy Practice Samford University McWhorter School of Pharmacy
Rheumatoid Arthritis Update Whitney White, Pharm.D., BCPS Associate Professor of Pharmacy Practice Samford University McWhorter School of Pharmacy Disclosures I declare that neither I nor any member of
More informationMMS Pharmacology Lecture 2. Antirheumatic drugs. Dr Sura Al Zoubi
MMS Pharmacology Lecture 2 Antirheumatic drugs Dr Sura Al Zoubi Revision Rheumatoid Arthritis Definition (RA): is the most common systemic inflammatory disease characterized by symmetrical inflammation
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationAdherence to Non-Infused Biologic Medications Used to Treat Rheumatoid Arthritis (PDC-RA)
Adherence to Non-Infused Biologic Medications Used to Treat Rheumatoid Arthritis (PDC-RA) Description The percentage of patients 18 years and older with rheumatoid arthritis (RA) who met the Proportion
More informationORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION
UnitedHealthcare Community Plan Medical Benefit Drug Policy ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION Policy Number: CS2018D0039J Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
More informationRheumatoid Arthritis. Update in Rheumatoid Arthritis Diagnosis and Therapy. RA: Chronic Joint Destruction and Disability What We Try to Prevent
Rheumatoid Arthritis Update in Rheumatoid Arthritis Diagnosis and Therapy Jonathan Graf, M.D. Associate Professor of Medicine, UCSF Division of Rheumatology, SFGH Director, UCSF Rheumatoid Arthritis Clinic
More informationActemra. Actemra (tocilizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.12 Subject: Actemra Page: 1 of 13 Last Review Date: September 20, 2018 Actemra Description Actemra
More informationAntirheumatic drugs. Rheumatic Arthritis (RA)
Antirheumatic drugs Rheumatic Arthritis (RA) Disease Modifying Antirheumatic drugs (DMARDs) DMARDs are used in the treatment of rheumatic arthritis RA and have been shown to slow the course of the disease,
More informationPatient #1. Rheumatoid Arthritis. Rheumatoid Arthritis. 45 y/o female Morning stiffness in her joints >1 hour
Patient #1 Rheumatoid Arthritis Essentials For The Family Medicine Physician 45 y/o female Morning stiffness in her joints >1 hour Hands, Wrists, Knees, Ankles, Feet Polyarticular, symmetrical swelling
More informationClinical Practice Guideline. Rheumatoid Arthritis (RA) Adult. Version
Clinical Practice Guideline Rheumatoid Arthritis (RA) Adult Version 1.1.2017 June 2017 Table of Contents Introduction... 5 Diagnosis... 8 Determining the Diagnosis... 8 Laboratory Tests...10 Patient Assessment...11
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 5 Last Review Date: March 17, 2017 Xeljanz Description Xeljanz, Xeljanz
More informationEvaluating Newer Targeted Therapies for Patients with Rheumatoid Arthritis: Addressing Unmet Needs in the Primary Care Practice
Evaluating Newer Targeted Therapies for Patients with Rheumatoid Arthritis: Addressing Unmet Needs in the Primary Care Practice Provided by Integrity Continuing Education, Inc. Supported by an educational
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 5 Last Review Date: March 18, 2016 Xeljanz Description Xeljanz, Xeljanz
More informationOtezla. Otezla (apremilast) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background
More informationRheumatoid Arthritis. By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University
Rheumatoid Arthritis By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University Introduction RA is a Chronic, Systemic, Inflammatory disorder of unknown etiology
More informationACTEMRA (TOCILIZUMAB) INJECTION FOR INTRAVENOUS INFUSION
ACTEMRA (TOCILIZUMAB) INJECTION FOR INTRAVENOUS INFUSION UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0043I Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
More informationBiologic therapy for Rheumatoid arthritis. Paul Etau Ekwom Physician and Rheumatologist
Biologic therapy for Rheumatoid arthritis Paul Etau Ekwom Physician and Rheumatologist Objectives Case presentation of patient with rheumatoid arthritis on a biologic therapy. Discuss biologic therapy
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara
More informationACTEMRA (tocilizumab)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced
More informationACTEMRA (TOCILIZUMAB) INJECTION FOR INTRAVENOUS INFUSION
ACTEMRA (TOCILIZUMAB) INJECTION FOR INTRAVENOUS INFUSION UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 284.9 T2 Effective Date: June 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE...
More informationORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION
ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0039J Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
More informationA Clinical Context Report
Rheumatoid Arthritis in Practice An Expert Commentary with Diane Horowitz, MD A Clinical Context Report Rheumatoid Arthritis in Practice Jointly Sponsored by: and Rheumatoid Arthritis in Practice Expert
More informationRheumatoid arthritis 2010: Treatment and monitoring
October 12, 2010 By Yusuf Yazici, MD [1] The significant changes in the way rheumatoid arthritis has been managed include earlier, more aggressive treatment with combination therapy. Significant changes
More informationRheumatoid arthritis
Rheumatoid arthritis 1 Definition Rheumatoid arthritis is one of the most common inflammatory disorders affecting the population worldwide. It is a systemic inflammatory disease which affects not only
More informationSynoviocytes. Macrophage. B cell C H R O N I C. Neutrophil. Mast cell I N F L A M M A T I O N. Tissue cell. Endothelial cell. Th1/Th17 IL17 IL22
DC IL12, IL23 chemokines, ECM, Co-stimulation IL17, IL22 IFNγ ± Macrophage peptidoglycan lipopolysaccharide heat shock proteins Th1/Th17 IL17 IL22 Cell contact, co-stimulation immune complexes acute phase
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,700 108,500 1.7 M Open access books available International authors and editors Downloads Our
More informationMEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib)
MEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib) Read this Medication Guide before you start taking XELJANZ and each time you get a refill. There may be new information. This Medication Guide does not
More informationIntroduction. Rheumatoid Arthritis. Rheumatoid Arthritis. Arthritis vs Rheumatoid Arthritis
Rheumatoid Arthritis Stuart Weisman, MD Boulder Medical Center, P.C. 303-622-3724 Introduction What is rheumatoid arthritis? How is it different than arthritis? What are the symptoms? How is it diagnosed?
More informationDr Daniel Ching. Rheumatology Therapeutic Clinical Trials Centre Timaru
Dr Daniel Ching Rheumatology Therapeutic Clinical Trials Centre Timaru Therapeutic Advances in Rheumatology GP CME Meeting, Dunedin, 18.08.2013 Dr Daniel Ching, MB FRCP FRACP Consultant Rheumatologist,
More informationPharmacy Management Drug Policy
SUBJECT: Cimzia (Certolizumab pegol) - for Ankylosing Spondylitis, Crohn s Disease, Psoriatic Arthritis and Rheumatoid Arthritis POLICY NUMBER: PHARMACY-07 EFFECTIVE DATE: 5/2009 LAST REVIEW DATE: 6/13/2018
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Subject: Cimzia Page: 1 of 5 Last Review Date: December 8, 2017 Cimzia Description Cimzia (certolizumab
More information2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients
2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients Dr Alberta Hoi Rheumatologist MBBS, FRACP, PhD NEW ERA IN MUSCULOSKELETAL MEDICINE New drugs - Biologics,
More information1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
More information1.0 Abstract. Title. Keywords. Rationale and Background
1.0 Abstract Title A Prospective, Multi-Center Study in Rheumatoid Arthritis Patients on Adalimumab to Evaluate its Effect on Synovitis Using Ultrasonography in an Egyptian Population Keywords Synovitis
More informationFirst Name. Specialty: Fax. First Name DOB: Duration:
Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:
More informationRheumatology Updates for the Primary Care Provider
Rheumatology Updates for the Primary Care Provider Jean Tayar, MD, RhMSUS Associate Professor Section of Rheumatology and Clinical Immunology Department of General Internal Medicine UT MD Anderson Cancer
More informationBACK FIGHT. It s time to. Take action today. Ask your rheumatologist about ORENCIA.
For moderate to severe Rheumatoid Arthritis (RA) It s time to FIGHT BACK Model, not actual patient. Take action today. Ask your rheumatologist about ORENCIA. What is ORENCIA? ORENCIA (abatacept) is a prescription
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More informationMedication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014
Medication Policy Manual Policy No: dru342 Topic: Otezla, apremilast Date of Origin: May 9, 2014 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1, 2015 IMPORTANT
More informationDr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria
Dr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria Inter-Balkan meeting Open the frontiers and exchange of experiences, 27 th April 2013, Rhodes, Greece Patients with
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cimzia Page: 1 of 5 Last Review Date: March 17, 2017 Cimzia Description Cimzia (certolizumab pegol)
More informationCosentyx. Cosentyx (secukinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx
More informationInflammation, rheumatoid arthritis and cardiovascular disease
Inflammation, rheumatoid arthritis and cardiovascular disease Yvette Meißner, Pharmacoepidemiology, German Rheumatism Research Centre www. chronische-entzuendung.org Outline I. Cardiovascular disease II.
More informationClinical Practice Guideline. Rheumatoid Arthritis (RA) Adult. Version
Clinical Practice Guideline Rheumatoid Arthritis (RA) Adult Version 1.1.2018 August 2018 Table of Contents Introduction... 5 Diagnosis... 8 Determining the Diagnosis... 8 Laboratory Tests... 11 Patient
More informationPharmacy Accreditation
RHEUMATOID ARTHRITIS: A FOCUS ON REDUCTION OF DISEASE PROGRESSION AND DISABILITY Geoffrey C. Wall, PharmD, FCCP, BCPS, CGP Professor of Clinical Sciences Drake University College of Pharmacy Internal Medicine
More informationRheumatoid Arthritis: Challenges and Opportunities in the Evolving Treatment Landscape ReachMD Page 1 of 9
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationSimponi / Simponi ARIA (golimumab)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 6 Last Review Date: September 15, 2016 Simponi / Simponi
More informationSIMPONI ARIA (GOLIMUMAB) INJECTION FOR INTRAVENOUS INFUSION
UnitedHealthcare Commercial Medical Benefit Drug Policy SIMPONI ARIA (GOLIMUMAB) INJECTION FOR INTRAVENOUS INFUSION Policy Number: PHA031 Effective Date: March 1, 2019 Table of Contents Page COVERAGE RATIONALE...
More informationPsoriatic Arthritis- Second Line Treatments
Psoriatic Arthritis- Second Line Treatments Second line treatments for Psoriatic Arthritis (PsA) are usually prescribed by a Rheumatologist, Dermatologist, or in a combined clinic where both the Dermatologist
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi
More informationTreating Rheumatologic Disease in Arizona: Good News, Bad News
Treating Rheumatologic Disease in Arizona: Good News, Bad News Jeffrey R. Lisse, M.D. Ethel P. McChesney Bilby Professor of Medicine Chief, Section of Rheumatology University of Arizona School of Medicine
More information- Clinical Background, Motivation and my Experience at F2F meeting
Predicting randomized clinical trial results with realworld evidence: A case study in the comparative safety of tofacitinib, adalimumab and etanercept in patients with rheumatoid arthritis - Clinical Background,
More informationAlthough this presentation includes information regarding pharmaceuticals (including products under development), the information is not intended as
Although this presentation includes information regarding pharmaceuticals (including products under development), the information is not intended as any advertisement and/or medical advice. Forward-Looking
More informationPerioperative Medicine:
Perioperative Medicine: Management of rheumatologic agents Divya Gollapudi, MD May 2016 Medical Operative Consult Clinic Harborview Medical Center Your patient Ms. L is a 55 year-old F w/ h/o RA who presents
More informationNew Evidence reports on presentations given at ACR Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab
New Evidence reports on presentations given at ACR 2009 Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab From ACR 2009: Rituximab Rituximab in combination with methotrexate
More informationJames R. O Dell, M.D. University of Nebraska Medical Center
Not everyone in the world needs a biologic: Lessons from TEAR and RACAT James R. O Dell, M.D. University of Nebraska Medical Center Disclosure Declaration James O Dell, MD Advisory Board for Crescendo,
More informationThe Role of the Physician Assistant in the Management of the RA Patient
For your information Clinical Professor of Medicine, David Geffen School of Medicine at UCLA Private practice, Tustin CA Investigator in clinical trials relevant to this lecture including: anti-tnf for
More informationRheumatoid arthritis and Psoriatic arthritis: a guide for Primary Care. Nina Flavin, MD Rheumatology Confluence Health April 13 th, 2018
Rheumatoid arthritis and Psoriatic arthritis: a guide for Primary Care Nina Flavin, MD Rheumatology Confluence Health April 13 th, 2018 No Disclosures Objectives Recognize early signs of RA/PsA what to
More informationMedical Management of Rheumatoid Arthritis (RA)
Medical Management of Rheumatoid Arthritis (RA) Dr Lee-Suan Teh Rheumatologist Royal Blackburn Hospital Educational objectives ABC Appreciate the epidemiology of RA Be able to diagnosis of RA Competent
More informationPsoriatic Arthritis- Secondary Care
Psoriatic Arthritis- Secondary Care Our Psoriatic Arthritis: First Line Treatments information sheet gives information on the treatments that can be prescribed by a GP, or that might be prescribed if the
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)
DERBYSHIRE JOINT AREA PRERIBING COMMITTEE (JAPC) Derbyshire commissioning guidance on biologic drugs f the treatment of Rheumatoid arthritis with methotrexate This algithm is a tool to aid the implementation
More informationReminder. Faculty Affiliation. Complete Session Pre- and Post-Test Complete Online Session Evaluation at End of Session. **Links found in Event App
Overcoming Barriers to the Early Recognition and Diagnosis of Rheumatoid Arthritis in Real-world Practice: Strategies to Expedite Treatment to Remission Provided by Integrity Continuing Education, Inc.
More informationClinical Policy: Tocilizumab (Actemra) Reference Number: ERX.SPMN.44
Clinical Policy: (Actemra) Reference Number: ERX.SPMN.44 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
Program Number 2017 P 3041-8 Program Step Therapy Medications UnitedHealthcare Pharmacy Clinical Pharmacy Programs *Orencia (abatacept) *This step criteria refers to the subcutaneous formulation of abatacept
More informationDrug selection in Rheumatoid Arthritis
Drug selection in Rheumatoid Arthritis PROFESSOR KHAN ABUL KALAM AZAD PROFESSOR, DEPARTMENT OF MEDICINE DHAKA MEDICAL COLLEGE Rheumatoid arthritis Autoimmune disease Onset generally occurs between 30 and
More informationPharmacy Management Drug Policy
SUBJECT: Inflammatory Conditions Clinical Review Prior Authorization (CRPA) Rx and Medical Drugs POLICY NUMBER: PHARMACY-73 EFFECTIVE DATE: 01/01/2018 LAST REVIEW DATE: 06/11/2018 If the member s subscriber
More informationRheumatoid Arthritis. Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011
Rheumatoid Arthritis Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011 The security of experience. The power of innovation. www.rgare.com Case Study
More informationCenter for Evidence-based Policy
P&T Committee Brief Targeted Immune Modulators: Comparative Drug Class Review Alison Little, MD Center for Evidence-based Policy Oregon Health & Science University 3455 SW US Veterans Hospital Road, SN-4N
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research
More informationClinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Cimzia ) is a tumor necrosis
More informationEarly synovitis clinics
Early synovitis clinics Jeremy Jones MD FRACP FAFRM Consultant Rheumatologist, Llandudno General Hospital Honorary Research Fellow School of Sport, Health and Exercise Sciences Bangor University RA medication
More informationMore Than Growing Pains: Therapeutic Review of Juvenile Idiopathic Arthritis (JIA)
More Than Growing Pains: Therapeutic Review of Juvenile Idiopathic Arthritis (JIA) Brittany A. Bruch, PharmD PGY2 Ambulatory Care Pharmacy Resident University of Iowa Hospitals and Clinics November 10,
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis
New Evidence reports on presentations given at EULAR 2012 Tocilizumab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Tocilizumab monotherapy is superior to adalimumab monotherapy
More informationSeronegative Arthritis. Dr Mary Gayed 25 th April 2018
Seronegative Arthritis Dr Mary Gayed 25 th April 2018 Overview Description of the conditions Discussion of symptoms & investigations that may be required Discussion of management and treatment Questions
More informationBasic Approach/Goals. Medical Management of Rheumatic Diseases. Acetaminophen. Anti-inflammatories (NSAIDs) Steroids.
Basic Approach/Goals Medical Management of Rheumatic Diseases Diane Lacaille, Rheumatologist ACE Workshop April 23, 2018 1) Symptom control: Acetaminophen, NSAIDs, steroids (intraart, po) 2) Prevention
More informationCell-Mediated Immunity and T Lymphocytes
Cell-Mediated Immunity and T Lymphocytes T helper (Th) Cells Peripheral lymhoid tissue thymus Lymphoid stem cell CD8+ CD4+ CD4+ Treg CD8+ CTL + antigen Cytotoxic T lymphocyte CD4+ Th Helper T cell CD4+
More informationActemra (tocilizumab) CG-DRUG-81
Market DC Actemra (tocilizumab) CG-DRUG-81 Override(s) Prior Authorization Approval Duration 1 year Medications Line of Business Quantity Limit Actemra (tocilizumab) vials VA MCD and All L-AGP May be subject
More informationRegulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.12 Subject: Entyvio Page: 1 of 7 Last Review Date: September 20, 2018 Entyvio Description Entyvio
More informationRheumatology Therapeutics: Perioperative DMARD Management, Infection and Malignancy Risks, Vaccination Considerations. Heather Hansen, MD
Rheumatology Therapeutics: Perioperative DMARD Management, Infection and Malignancy Risks, Vaccination Considerations Heather Hansen, MD Objectives Know Broad Categories of Rheumatoid Arthritis Medications
More informationRheumatoid Arthritis: When to Start and when to Stop anti-tnf Therapy
Rheumatoid Arthritis: When to Start and when to Stop anti-tnf Therapy [ Cuando iniciar o detener la tx anti-tnf?] Asociacion Costatarricense Medicina Interna August 7, 2015 Arthur Weinstein, MD, FACP,
More informationBiologics for Autoimmune Diseases
Biologics for Autoimmune Diseases Goal(s): Restrict use of biologics to OHP funded conditions and according to OHP guidelines for use. Promote use that is consistent with national clinical practice guidelines
More information